Ep. 370 - Calmer waters for FDA; Servier, Lilly deals
From BioCentury This Week · · 34 min
This plays from the publisher's own server. We do not host a copy.
Description
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin discusses how FDA’s new, interim leaders have changed the tone (https://www.biocentury.com/article/659669) at the agency and why they are putting medicines derailed (https://www.biocentury.com/article/659645) under former FDA Commissioner Marty Makary back on track. Usdin also highlights (https://www.biocentury.com/article/659595) FDA’s new real-time clinical trials initiative. BioCentury’s analysts then turn to deals, including an analysis of the 20 deals Eli Lilly has done this year; Servier’s move to expand in neurology (https://www.biocentury.com/article/659622) via BD; and Monday’s billion-dollar deals by Incyte, which will acquire (https://www.biocentury.com/article/659686) Vega Therapeutics, and Johnson & Johnson, which is buying (https://www.biocentury.com/article/659688) Firefly Bio. The team also discusses Grand Rounds U.S., held last week in Seattle, including the conference’s Rising Star (https://www.biocentury.com/article/659662) prize winner Sylvain Simon of Fred Hutchinson Cancer Center.
View full story: https://www.biocentury.com/article/659699
#FDA #BiopharmaDeals #ClinicalTrials #BiotechMA #GrandRoundsUS
01:23 - Grand Rounds Seattle Takeaways 04:43 - FDA's New Leaders 11:48 - FDA's Real Time Trials Pilot 20:40 - Servier Bets on Neuro 25:33 - Lilly's Deal Spree 30:21 - Dealmaking Roundup
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)